1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–8.
2. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature. 2004;431:371–8.
3. Durcan N, Murphy C, Cryan S. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm. 2008;5:566–99.
4. Kim SH, Jeong JH, Kim T, Kim SW, Bull DA. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm. 2009;6:718–26.
5. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov. 2004;3:318–29.
6. Jeong JH, Kim SW, Park TG. Molecular design of functional polymers for gene therapy. Prog Polym Sci. 2007;32:1239–74.
7. Kim SH, Jeong JH, Ou M, Yockman JW, Kim SW, Bull DA.
Cardiomyocyte-targeted siRNA delivery by prostaglandin E2-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis. Biomaterials. 2008;29:4439–46.
8. Smedt SCD, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res. 2000;17:113–26.
9. Tomlinson E, Rolland AP. Controllable gene therapypharmaceutics of non-viral gene delivery systems. J Control Release. 1996;39:357–72.
10. Kwoh DT, Coffin CC, Lollo CP, Jovenal J, Banaszczyk MG, Mullen P, et al. Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim Biophys Acta. 1999;1444:171–90.
11. Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J. 2007;9:E92–104.
12. Plank C, Mechtler K, Szoka Jr FC, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996;7:1437–46.
13. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control R
14. Shah SA, Brunger AT. A crystal structure of a statically disordered 17 base-pair RNA duplex: principles of RNA crystal packing and its effect on nucleic acid structure. J Mol Biol.1999;285:1577–88.
15. Kebbekus P, Draper DE, Hagerman P. Persistence length of RNA. Biochemistry. 1998;34:4354–7.
16. Mok H, Lee SH, Park JW, Park TG. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater. 2010;9:272–8.
17. Lee SY, Huh MS, Lee S, Lee SJ, Chung H, Park JH, et al.
Stability and cellular uptake of polymerized siRNA (poly-siRNA)/ polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release. 2010;141:339–46.
18. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF.
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977;252:3582–6.
19. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;11:3578–81.
20. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10:1451–8.
21. Veronese FM, Harris JM. Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev. 2002;54:453–6.
22. Gursahani H, Riggs-sauthier J, Pfeiffer J, Lechuga-Ballesteros D, Fishburn CS. Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. J Pharm Sci. 2009;98:2847–56.
23. Jeong JH, Kim SW, Park TG. A new antisense oligonucleotide delivery system based on self-assembled ODNPEG hybrid conjugate micelles. J Control Release. 2003;93:183–91.
24. Jeong JH, Kim SH, Kim SW, Park TG. Intracellular delivery of poly(ethylene glycol) conjugated antisense oligonucleotide using cationic lipids by formation of self-assembled polyelectrolyte complex micelles. J Nanosci Nanotechnol. 2006;6:2790– 5.
25. Osada K, Christie RJ, Kataoka K. Polymeric micelles from poly (ethylene glycol)–poly(amino acid) block copolymer for drug and gene delivery. J R Soc Interface. 2009;6:S325–39.
26. Petersen H, Fechner PM, Martin AL, Kunath K, Stolnik S, Roberts CJ, et al. Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system.
Bioconjug Chem. 2002;13:845–54.
27. Kunath K, Harpe A, Petersen H, Fischer D, Voigt K, Kissel T, et al. The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NFκB decoy in mice. Pharm Res. 2002;19:810–7.
28. Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Aicds Symp Ser. 2005;49:17–8.
29. Kim SH, Mok H, Jeong JH, Kim SW, Park TG. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem. 2006;17:241–4.
30. Naeyea B, Raemdoncka K, Remauta K, Sproatb B, Demeestera J, De Smedta SC. PEGylation of biodegradable dextran nanogels for siRNA delivery. Eur J Pharm Sci. 2010;40:342–51.
31. Tamura A, Oishi M, Nagasaki Y. Efficient siRNA delivery based on PEGylated and partially quaternized polyamine nanogels: enhanced gene silencing activity by the cooperative effect of tertiary and quaternary amino groups in the core. J Control Release. 2010;146:378–87.
32. Noh SM, Park MO, Shim G, Han SE, Lee HY, Huh JH, et al.
Pegylated poly-L-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release. 2010;145:159–64.
33. Kim WJ, Yockmana JW, Lee M, Jeong JH, Kim Y, Kim SW.
Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release. 2005;106:224–34.
34. Hong JW, Park JH, Huh KM, Chung H, Kwon IC, Jeong SY.
PEGylated polyethylenimine for in vivo local gene delivery based on lipiodolized emulsion system. J Control Release. 2004;99:167– 76.
35. Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH, et al. Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release. 2005;107:562–70.
36. Lee H, Jeong JH, Park TG. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J Control Release. 2002;79:283–91.
37. Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethyleneglycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res. 2005;22:956–65.
38. Lee H, Kim TH, Park TG. A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor. J Control Release. 2002;83:109–19.
39. Meyer O, Kirpotin D, Hong K, Sternberg B, Park JW, Woodlei MC. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem. 1998;273:15621–7.
40. Harada A, Togawa H, Kataoka K. Physicochemical properties and nuclease resistance of antisenseoligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly (ethylene glycol)–poly(L-Lysine) block copolymers. Eur J Pharm Sci. 2001;13:35–42.
41. Shi F, Wasungu L, Aomden A, Stuart MCA, Polushkin E, Engberts JBFN, et al. Interference of poly(ethylene glycol)–lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem J. 2002;366:333–41.
42. Oishi M, Nagatsugi F, Sasaki S, Nagasaki Y, Kataoka K. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. Chembiochem. 2005;6:718–25.
43. Jeong JH, Kim SH, Kim SW, Park TG. In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles. J Biomater Sci Polym Ed. 2005;16:1409–19.
44. Oishi M, Sasaki S, Nagasaki Y, Kataoka K. pH-Responsive oligodeoxynucleotide (ODN)-poly(ethylene glycol) conjugate through acid-labile β-thiopropionate linkage: preparation and polyion complex micelle formation. Biomacromolecules. 2003;4:1426–32.
45. Jeong JH, Kim SH, Kim SW, Park TG. Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly (ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth. Bioconjug Chem. 2005;16:1034–7.
46. Kim SH, Jeong JH, Mok H, Lee SH, Kim SW, Park TG. Folate receptor targeted delivery of polyelectrolyte complex micelles prepared from ODN-PEG-folate conjugate and cationic lipids. Biotechnol Prog. 2007;23:232–7.
47. Oishi M, Nagasaki Y, Itaka K, Nishiyama N, Kataoka K.
Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc. 2005;127:1624–5.
48. Zhang M, Ishii A, Nishiyama N, Matsumoto S, Ishii T, Yamasaki Y, et al. PEGylated calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA delivery. Adv Mater. 2009;21:3520–5.
49. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem. 2008;19:2156–62.
50. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release. 2006;116:123–9.
51. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. 2008;129:107–16.
52. Lee SH, Kim SH, Park TG. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem Biophys Res Commun. 2007;357:511–6.
53. Mok H, Park TG. Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA. Biopolymers. 2008;89:881–8.
54. Lee SH, Bae KH, Kim SH, Lee KR, Park TG. Aminefunctionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. Int J Pharm. 2008;364:94–101.
55. Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm. 2008;5:622–31.
56. Jeong JH, Mok HJ, Oh Y, Park TG. siRNA conjugate delivery systems. Bioconjug Chem. 2009;20:5–14.
57. Jeong JH, Kim SW, Park TG. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug Chem. 2003;14:473–9.
58. Scanlon KJ. Anti-genes: siRNA, ribozymes and antisense. Curr Pharm Biotechnol. 2004;5:415–20.
59. de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm. 2009;71:490–504.
60. Brown KM, Chu C, Rana TM. Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol. 2005;12:469–70.
61. Jung S, Lee SH, Mok H, Chung HJ, Park TG. Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight. J Control Release. 2010;144:306–13.
62. Oishi M, Nagasaki Y, Nishiyama N, Itaka K, Takagi M, Shimamoto A, et al. Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated poly(ethylene glycol)siRNA conjugate formulated in PEGylated polyplexes. ChemMedChem. 2007;2:1290–7.
63. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, et al.
RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003;42:7967–75.
64. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem.2005;48:4247–53.
65. Shah S, Friedman SH. Tolerance of RNA interference toward modifications of the 5′ antisense phosphate of small interfering RNA. Oligonucleotides. 2007;17:35–43.
66. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003;31:589–95.
67. Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, et al. Lung delivery studies using siRNA conjugated to TAT(48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 2007;18:1450–9.
68. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett.2004;558:63–8.
69. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA. 2002;99:12617–21.
70. Meong F, Hennink WE, Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials. 2009;30:2180–98.
71. Werth S, Urban-Klein B, Dai L, Hobel S, Grzelinski M, Bakowsky U, et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release. 2006;112:257–70.
72. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A.
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12:461–6.
73. Mok H, Park TG. Functional polymers for targeted delivery of nucleic acid drugs. Macromol Biosci. 2009;9:731–43.
74. Wagner E. Application of membrane-active peptides for nonviral gene delivery. Adv Drug Deliv Rev. 1999;38:279–89.
75. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC.
Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry. 1997;36:3008–17.
76. Choi SH, Lee SH, Park TG. Temperature-sensitive pluronic/poly (ethylenimine) nanocapsules for thermally triggered disruption of intracellular endosomal compartment. Biomacromolecules. 2006;7:1864–70.
77. Choi SH, Lee J, Choi S, Park TG. Thermally reversible pluronic/ heparin nanocapsules exhibiting 1000-fold volume transition. Langmuir. 2006;22:1758–62.
78. Lee K, Bae KH, Lee Y, Lee SH, Ahn C, Park TG. Pluronic/ polyethylenimine shell crosslinked nanocapsules with embedded magnetite nanocrystals for magnetically triggered delivery of siRNA. Macromol Biosci. 2010;10:239–45.
79. Storhoff JJ, Elghanian R, Mucic RC, Mirkin CA, Letsinger RL.
One-pot colorimetric differentiation of polynucleotides with single base imperfections using gold nanoparticle probes. J Am Chem Soc. 1998;120:1959–64.
80. Otsuka H, Akiyama Y, Nagasaki Y, Kataoka K. Quantitative and reversible lectin-induced association of gold nanoparticles modified with α-lactosyl-ω-mercapto-poly(ethylene glycol). J Am Chem Soc. 2001;123:8226–30.
81. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, Curley SA.
Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotech. 2008;6:2.
82. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006;312:1027–30.
83. Sandhu KK, McIntosh CM, Simard JM, Smith SW, Rotello VM.
Gold nanoparticle-mediated transfection of mammalian cells. Bioconjug Chem. 2002;13:3–6.
84. Niidome T, Nakashima K, Takahashi H, Niidome Y. Preparation of primary amine-modified gold nanoparticles and their transfection ability into cultivated cells. Chem Commun. 2004;10:1978–9.
85. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644–70.
86. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–4.
87. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, et al.
Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol. 2005;26:1087–91.
88. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomized phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882–7.
89. Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, et al. Codelivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials. 2010;31:2408–16.
90. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–84.
91. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185– 8.
92. Al-Abd AM, Lee SH, Kim SH, Cha J, Park TG, Lee SJ.
Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro. J Control Release. 2009;137:130–5.
93. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59:748–58.
94. Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopeckova P, et al. Pegylated polyethylenimine-Fab’ antibody fragment conjugate for targeted gene delivery to human ovarian carcinoma cells. Bioconjug Chem. 2003;14:989–96.